Bleeding Disorders

Comparison of Approaches for Detection of Type 1 von Willebrand Disease

Researchers sought to determine whether the HemosIL VWF activity assay would be an effective method for identifying VWD.

Ibrutinib May Reduce Risk of Bleeding Events in Acquired von Willebrand Syndrome Secondary to Waldenström Macroglobulinemia

By

Jonathan Goodman, MPhil

Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.

VWF Associated With Thrombotic Complications in Patients With COVID-19

By

Patricia Chaney

Researchers sought to determine whether von Willebrand factor may be a potential target for therapies to address thrombotic complications in patients with COVID-19.

Mobile Health Technology in the Management of Hemophilia

By

Patricia Chaney

Researchers sought to determine whether mobile health technology may play a helpful role in the management of hemophilia.

Positive Impact Seen With Neurodynamics Nerve Flossing on Femoral Neuropathy in Patients With Hemophilia

By

Lauren Dembeck, PhD

Researchers sought to determine whether the neurodynamics nerve flossing technique would be beneficial in the treatment of femoral neuropathy in children with hemophilia.

MarzAA Safe and Efficacious as Prophylactic Treatment in Patients With Severe Hemophilia With Inhibitors

By

Lauren Dembeck, PhD

Researchers sought to determine whether a novel variant of activated human factor VII Marzeptacog alfa (activated) would be effective as prophylactic treatment in patients with severe congenital hemophilia with inhibitors.

Bleeding Patterns of Infants and Toddlers With von Willebrand Disease

By

Vicki Moore, PhD

Researchers sought to define bleeding patterns and other characteristics in infants and toddlers with von Willebrand disease.

Recombinant FVIIIFc May Be Cost Effective for Treating Severe Hemophilia A

By

Patricia Chaney

Researchers sought to determine whether rFVIII Fc-fusion protein would be a cost-effective treatment option for patients with severe hemophilia A.

In Silico Reduction in Antithrombin Level in Patients With Hemophilia A

By

Vicki Moore, PhD

Researchers sought to determine whether antithrombin would have the potential to restore thrombin generation in patients with hemophilia A.

Standardized Ultrasound Guidelines Needed for Patients With Hemophilia, According to Expert Panel

By

Jonathan Goodman, MPhil

Researchers sought to determine whether clearer guidelines are needed for utilizing ultrasounds to assess musculoskeletal outcomes in patients with hemophilia.

Aerobic, Resistance, Combined Training Improves Lipid Profiles and Quality of Life in Overweight Patients With Hemophilia A

By

Lauren Dembeck, PhD

Researchers sought to determine whether combined training would improve lipid profiles and quality of life in patients with hemophilia A who were overweight.

Continuing Prophylaxis into Young Adulthood Improves Outcomes for Patients With Hemophilia

By

Patricia Chaney

People with hemophilia tend to have less adherence to prophylaxis as they transition to adulthood but continuing the therapy can improve their joint health.

Plasma-Derived Von Willebrand Factor/FVIII Safe, Effective in Patients Younger Than 12 With Hemophilia A

By

Patricia Chaney

Researchers sought to determine whether plasma-derived von Willebrand factor/factor VIII would be safe and effective in patients with hemophilia A younger than 12 years.

Joint Health Deteriorated in Patients With Hemophilia A During COVID-19 Lockdown

By

Patricia Chaney

Researchers sought to determine the impact of the COVID-19 lockdown on patients with hemophilia.

Patients With Hemophilia Can Safely Perform Knee Extensions

By

Patricia Chaney

Researchers sought to determine whether patients with hemophilia could safely perform moderate intensity training without adverse effects.

Emicizumab May Improve Outcomes for Acquired Hemophilia A

By

Patricia Chaney

Researchers sought to determine whether emicizumab would help improve outcomes for patients with acquired hemophilia A.

Phase 3 Results Confirm Emicizumab Is Safe for Hemophilia A

By

Patricia Chaney

Researchers sought to confirm whether emicizumab is safe for treating patients with hemophilia A with factor VIII inhibitors.

Recombinant von Willebrand Factor Prophylaxis Effective at Preventing Bleeding in Patients With von Willebrand Disease

By

Vicki Moore, PhD

Researchers sought to determine whether recombinant VWF would be effective in reducing spontaneous bleeding for patients with severe VWD previously treated in an on-demand manner.

Monoclonal Antibody Marstacimab Appears to Be Safe and Effective in Patients With Severe Hemophilia

By

Lauren Dembeck, PhD

Researchers sought to determine whether marstacimab would be effective in treating patients with severe hemophilia.

Gene Therapy Reduces Bleed Rates Among Patients With Hemophilia A

By

Jonathan Goodman, MPhil

Researchers sought to determine whether valoctocogene roxaparvovec would reduce the risk of bleeding and rate of factor VIII infusion in patients with hemophilia A.

FDA Issues Safety Alert Regarding Use of Hydroxyethyl Starch Products

By

Brian Park, PharmD

There are currently 4 FDA-approved hydroxyethyl starch products on the market.

Blood Shortage Causes Surgery Delays in New England

While periodic, localized blood shortages are not uncommon, this shortage is ‘unprecedented in its scope.

Updates on the Etiology, Diagnosis, Management of von Willebrand Syndrome and Hemophilia A

By

Patricia Chaney

Acquired hemophilia A (AHA) and acquired von Willebrand syndrome (aVWS) are rare, life-threatening bleeding disorders that occur in patients with no bleeding history and no family history of a bleeding disorder.

Heparin and COVID-19: Case Studies Suggest Small Risk of Hematoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether there was a risk of developing IPH in patients with COVID-19 treated with heparin.

First-in-Human Results Show Promise With BT200, a New Anti-von Willebrand Factor Agent

By

Vicki Moore, PhD

Researchers sought to determine whether BT200, a new anti-von Willebrand factor, would have efficacy in patients with von Willebrand disease.

Novel Tool Developed to Measure the Impact of Hemophilia on Families

By

Lauren Dembeck, PhD

Researchers have developed and validated a novel tool, the Hemophilia Family Impact Tool (H-FIT) to measure the impact of hemophilia on families.

More Bleeding Events After PCI in Women With Baseline Risk Factors

By

Cardiology Advisor Contributing Writer

The researchers explored the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin.

ABO-Incompatible Platelet Transfusion May Lead to Worse Clinical Outcomes in ICH

By

Jonathan Goodman, MPhil

Researchers sought to determine whether transfusing ABO-incompatible platelets would lead to worse clinical outcomes and slower platelet recovery in patients with ICH.

Agreement of Clinical, Ultrasound Tools for Joint Health in Children With Hemophilia

By

Patricia Chaney

Researchers sought to determine whether clinical and ultrasound assessment tools generally agree in their determinations of joint health for children with hemophilia on prophylaxis.

Feasibility of Eculizumab Discontinuation Based on Genetics in Atypical Hemolytic Uremic Syndrome

By

Patricia Chaney

Researchers sought to determine whether eculizumab discontinuation is feasible for patients with atypical hemolytic uremic syndrome when a strategy accounts for genetic variants.

Characteristics of Infants, Toddlers With von Willebrand Disease

By

Patricia Chaney

Researchers sought to determine the characteristics and diagnosis of infants and toddlers diagnosed with von Willebrand disease.

Methods to Evaluate Joint Arthropathy in Patients With Hemophilia Show Correlation

By

Vicki Moore, PhD

Researchers showed there was a correlation between 2 methods of scoring hemophilic arthropathy in pediatric patients with hemophilia.

Prophylactic Antihemophilic Factor May Help Preserve Joint Health in Patients With Hemophilia A

By

Patricia Chaney

Researchers sought to determine whether patients with moderate or severe hemophilia A may benefit from early prophylactic antihemophilic factor (recombinant).

Human Fibrinogen Concentrate Shows Favorable Pharmacokinetics for Bleeding Episodes in Congenital Fibrinogen Deficiency

By

Patricia Chaney

Researchers sought to determine whether human fibrinogen concentrate would have favorable pharmacokinetics for adult, adolescent, and pediatric patients with congenital fibrinogen deficiency.

Hemophilia B Shows High Health Care Cost Burden

By

Patricia Chaney

Researchers showed that adult men with hemophilia B had annual health care costs that totaled more than 25-fold higher than matched controls.

Long-Term Use of BAY 94-9027 Is Safe and Effective in Pediatric Patients With Severe Hemophilia A

By

Vicki Moore, PhD

Researchers sought to determine whether using BAY 94-9027 long-term was safe and effective in pediatric patients with severe hemophilia A.

Hemophilia: What Your Patients Need to Know

By

Steve Fiorillo

Hemophilia is a bleeding disorder caused by a genetic mutation that is often inherited. Patients who are at risk and parents or caregivers of children at risk of hemophilia may need additional education about what causes hemophilia and how it is diagnosed and treated.

Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia

By

Jonathan Goodman, MPhil

Researchers conducted 2 sets of literature reviews to determine whether the professional society recommendations for >50% factor levels during labor in patients with hemophilia was accurate.

Recombinant Factor VIII-Fc Fusion Protein for Hemophilia A Management

By

Vicki Moore, PhD

Researchers sought to determine whether recombinant factor VIII-Fc fusion protein would have greater efficacy as prophylaxis therapy over emicizumab in patients with hemophilia A.

Major Bleeding Linked to Anticoagulant Overdose in ICU Patients With COVID‑19

By

Lauren Dembeck, PhD

Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.

Recombinant von Willebrand Factor Is an Effective Treatment for Patients With von Willebrand Disease

By

Vicki Moore, PhD

Researchers performed an analysis to determine whether recombinant VWF given with surgery would be safe and effective in preventing bleeding in patients with VWD.

Manual Therapy Improves Joint and Quality of Life Outcomes in Hemophilic Arthropathy

By

Jonathan Goodman, MPhil

Researchers sought to determine whether physiotherapy and exercise would be an effective therapy for increasing functionality, joint health, and quality of life in patients with hemophilic arthropathy of the elbow.

Evaluation of BAX 335 Treatment in Patients With Hemophilia B

By

Vicki Moore, PhD

A new study suggests that treatment of patients with hemophilia B with BAX 335 gene therapy may be limited by a feature of coding sequence.

Some Patients With Hemophilia Report Superior Quality of Life Than the General Public

By

Vicki Moore, PhD

In a recent study, patients with hemophilia demonstrated a disability paradox, compared with members of the general population.

Cognitive Behavioral Therapy Effective Strategy for Chronic Pain Management in Hemophilia

By

Ariela Katz

DECKNonpharmacologic treatment with cognitive-behavioral therapy combined with physiotherapy may be an effective pain management strategy for patients with severe hemophilia.

Major Bleeding Linked to Anticoagulant Overdose in ICU Patients With COVID‑19

By

Lauren Dembeck, PhD

Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.

von Willebrand Factor Antigen to ADAMTS13 Ratio May Cause Immunothrombosis in COVID-19

By

Patricia Chaney

Does the von Willebrand factor antigen/ADAMTS13 ratio contribute to immunothrombosis and predict mortality in patients with COVID-19?

Fibrin-Specific Nanogels May Improve Result in Disseminated Intravascular Coagulation

By

Jonathan Goodman, MPhil

Results of a rodent model show that fibrin-specific core-shell nanogels with a tissue-type plasminogen activator warrants more study as a treatment for patients with DIC.

Bleeding Disorders: What Your Patients Need to Know

By

Steve Fiorillo

Whether inherited or acquired, bleeding disorders can cause significant pain, inconvenience, and stress in a person’s life. When patients think they or a loved one may have a bleeding disorder, what should they know?

Mild to Moderate Hemophilia: Experts Discuss Challenges and Propose Solutions

By

Caleb Rans, PharmD

A group of US-based hemophilia experts summarized unmet needs in mild to moderate hemophilia and provided suggestions for healthcare professionals to optimally manage their patients with this challenging condition.

Postural Balance Sign of Joint Health in Pediatric Patients With Hemophilia

By

Patricia Chaney

Pediatric patients with hemophilia may have impairments in postural balance, which could be an early sign of musculoskeletal disorders, and its assessment should be included in evaluations.